These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44 related articles for article (PubMed ID: 14666910)
21. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis. Psevdos G; Gonzalez E; Sharp V AIDS Read; 2009; 19(6):245-8. PubMed ID: 19642243 [TBL] [Abstract][Full Text] [Related]
22. Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure. Ter Heine R; Huitema AD; Jansen RS; Smits PH; van Gorp EC; Wagenaar JF; Beijnen JH; Mulder JW Antivir Ther; 2009; 14(2):299-301. PubMed ID: 19430105 [TBL] [Abstract][Full Text] [Related]
24. NRTI-related mitochondrial toxicity in an HIV-infected woman. Jenny-Avital ER AIDS Clin Care; 2003 Oct; 15(10):87-9. PubMed ID: 14666921 [No Abstract] [Full Text] [Related]
25. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. Irizarry-Alvarado JM; Dwyer JP; Brumble LM; Alvarez S; Mendez JC AIDS Read; 2009 Mar; 19(3):114-21. PubMed ID: 19334328 [TBL] [Abstract][Full Text] [Related]
26. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821 [TBL] [Abstract][Full Text] [Related]
27. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen. Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016 [TBL] [Abstract][Full Text] [Related]
28. Longitudinal studies of the role of NRTIs in fat loss. Currier J AIDS Clin Care; 2002 Dec; 14(12):106-7. PubMed ID: 12510657 [No Abstract] [Full Text] [Related]
29. Protection from nuke side effects. TreatmentUpdate; 2002 Dec; 14(9):3-4. PubMed ID: 12593383 [No Abstract] [Full Text] [Related]
32. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982 [TBL] [Abstract][Full Text] [Related]
33. Warning against tenofovir + ddI + 3TC, and "triple nuke" combinations. AIDS Treat News; 2003 Oct; (395):2-3. PubMed ID: 14666910 [TBL] [Abstract][Full Text] [Related]
34. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents. Gulick R AIDS; 1998; 12 Suppl 3():S17-22. PubMed ID: 15168719 [TBL] [Abstract][Full Text] [Related]
35. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid. Sax PE AIDS Clin Care; 2005 Jan; 17(1):6-7. PubMed ID: 15717372 [No Abstract] [Full Text] [Related]